• Dry Cracked Skin
  • General Dermatology
  • Impetigo
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Surgery
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Inflamed Skin

Strathspey Crown acquires Evolus

Article

Strathspey Crown Holdings has acquired Evolus, which will allow Strathspey Crown’s wholly-owned subsidiary, Alphaeon Corporation, the exclusive license to market the botulinum toxin type A product Evosyal.

 

Strathspey Crown Holdings has acquired Evolus, which will allow Strathspey Crown’s wholly-owned subsidiary, Alphaeon Corporation, the exclusive license to market the botulinum toxin type A product Evosyal.

Evosyal is developed by Seoul, South Korea manufacturer Daewoong. The product has a 900 kDa neurotoxin molecular complex with a high purity, according to a news release.

Alphaeon launched in July 2013 and the following month it acquired the exclusive U.S. license to Teoxane Laboratories’ full portfolio of hyaluronic acid-based dermal fillers and other cosmetic products marketed as Teosyal.

Evosyal and Teosyal will be marketed pending approval by the Food and Drug Administration. Teosyal is already used widely as a dermal filler in Europe.

 

Related Videos
© 2024 MJH Life Sciences

All rights reserved.